All issues
Volume 24 (2009)
- Issue 6 Pages 572-
- Issue 5 Pages 468-
- Issue 4 Pages 384-
- Issue 2 Pages 96-
- Issue 1 Pages 28-
Volume 24, Issue 4
Displaying 1-6 of 6 articles from this issue
- |<
- <
- 1
- >
- >|
Feature articles “Basic and clinical research for DDS of hormones” Editor : Toshiharu Yamaguchi
-
Hiroyuki Yoshino2009 Volume 24 Issue 4 Pages 384-393
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSWith the recent great progress in gene technology and in chemotherapy, many hormonal drugs have been developed and offered in clinical places contributing to patients with providing the advanced hormonal therapy. Currently, about ninety hormonal drugs and more than five hundred medicinal products are clinically used in Japan. Nevertheless, due to various reasons, including technical feasibility, cost problems and regulatory issues, only limited products utilize drug delivery technology.
This article reviews the hormonal DDS products currently available in the market and also the problems or difficulties in the development of DDS products are discussed.View full abstractDownload PDF (455K) -
Megumu Higaki2009 Volume 24 Issue 4 Pages 394-401
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSThe observed strong therapeutic benefit obtained with the stealth nanosteroid in experimental arthritis may have been due to prolonged blood circulation and targeting to the inflamed joint in addition to its sustained release in situ.View full abstractDownload PDF (626K) -
Mariko Morishita2009 Volume 24 Issue 4 Pages 402-407
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSThere are more than 246 million patients with diabetes mellitus in the world. Approximately 10∼15% of them suffer from diabetes mellitus type I, which is characterized by deficit of insulin synthesis in pancreas. Type 1 is lethal unless treated with exogenous insulin. Injection is the traditional and still most common method for administering insulin;jet injection, indwelling catheters. Therefore, the quest to eliminate the needle from insulin delivery and to replace it with non- or less-invasive alternative routes has driven rigorous pharmaceutical research to replace the injectable forms of insulin. Recently, various approaches have been studied involving many strategies using various technologies have shown success in delivering insulin, which are designed to overcome the inherent barriers for insulin uptake across the gastrointestinal tract, mucosal membranes and skin. This review examines some of the many attempts made to develop alternative, more convenient routes for insulin delivery to avoid existing long-term dependence on multiple subcutaneous injections and to improve the pharmacodynamic properties of insulin. In addition, this review summarized the noninvasive technologies and devices that succeeded in commercialization, and also focused on major new milestones in modern insulin delivery for the effective treatment of diabetes.View full abstractDownload PDF (337K) -
Mitsuko Takenaga, Rie Igarashi2009 Volume 24 Issue 4 Pages 408-414
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSProstaglandin E1(PGE1)is one of the lipid mediators and has potent biological activities such as inhibitor of platelet aggregation, and vasodilator. Lipid microspheres consist of egg yolk lecithin and soybean oil (o/w emulsion), have a diameter of 200∼300 nm, and preferentially accumulate in vascular lesion and inflammatory site. Therefore, PGE1 incorporated in lipid microsphere (Lipo PGE1 preparation) was efficiently delivered to target lesion, and more effective in human being as well as animal models. Lipo PGE1 preparation was introduced onto the Japanese market in 1988, and now applicable in both Korea and China, and has contributed to improving the condition of patients with arteriosclerosis obliterans, peripheral vascular diseases, and so on.View full abstractDownload PDF (469K) -
Takamitsu Inoue, Chikara Ohyama, Tomonori Habuchi2009 Volume 24 Issue 4 Pages 415-420
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSApproximately 80∼90% of untreated prostate cancer is androgen dependent for its proliferation and survival. It is standard to treat patients with metastatic prostate cancer by hormonal rather than definitive therapy such as radical prostatectomy or external radiotherapy. The purpose of hormonal therapy in prostate cancer is to decrease the signal to the androgen receptor which leads to apoptosis and diminished proliferation of prostate cancer cells. Currently, surgical castration, luteinizing hormone-releasing hormone agonists (LHRH agonists), antiandrogens and glucocorticoids are available as hormonal therapies in Japan. This article reviewed the development of a sustained-releasing system of LHRH agonists which was clinically applied by the unique drug delivery system. This system enabled male patients to be kept under the castrated androgen level without orchiectomy and relieves patients' mental and physical burden.View full abstractDownload PDF (426K) -
Yoshinori Ito2009 Volume 24 Issue 4 Pages 421-425
Published: 2009
Released on J-STAGE: October 30, 2009
JOURNAL FREE ACCESSEndocrine therapy plays a central role of systemic treatment for breast cancer. Luteinizing hormone-releasing hormone (LHRH) agonist, such as goserelin or leuprorelin is effective to premenopausal hormone-receptor positive breast cancer through medical ovarian ablation. Both slowly releasing agents are administered by subcutaneous injection with an interval of one or three months.
Fulvestrant, a pure antiestrogen, that is intramuscularly given every 4 weeks, is active against tamoxifen or aromatase-inhibitor resistant breast cancer. Nanoparticle conjugated with tamoxifen or LHRH agonist may enhance antitumor activity.View full abstractDownload PDF (386K)
- |<
- <
- 1
- >
- >|